Diagnostic Lab Testing Transparency Act

Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship H.R. 9849 - Medical Laboratory Personnel Shortage Relief Act of 2024 H.R. 3248 - Diagnostic Lab Testing Transparency Act H.R. 5378 - Lower Costs, More Transparency Act H.R. 2369 - the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 H.R. 88188 - American Privacy Rights Act of 2024 Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation CMS policies related to Medicare Advantage Engagement with executive branch departments/agencies regarding influenza A (H5) "Avian Flu"

Client expense: $390,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, test coding and pricing, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; price transparency for clinical laboratory services, FY 2024 budget and appropriations processes, FDA regulation of clinical laboratory services. Saving Access to Laboratory Services Act H.R. 2377/S. 1000; H.R. 3791, Improving Data in Public Health Act; H.R. 3248, Diagnostic Lab Testing Transparency Act; H.R. 5378, Lower Costs, More Transparency Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act.

Client expense: $375,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce H.R. 3248 - Diagnostic Lab Testing Transparency Act H.R. 5378 - Lower Costs, More Transparency Act H.R. 2369 - the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation

Client expense: $430,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship H.R. 9849 - Medical Laboratory Personnel Shortage Relief Act of 2024 H.R. 3248 - Diagnostic Lab Testing Transparency Act H.R. 5378 - Lower Costs, More Transparency Act H.R. 2369 - the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 H.R. 88188 - American Privacy Rights Act of 2024 Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation CMS policies related to Medicare Advantage Engagement with executive branch departments/agencies regarding influenza A (H5) "Avian Flu"

Client expense: $410,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act

Client expense: $193,594 · Firm income: Not reported

HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver PREVENT Pandemics Act CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA S 2140 - Patient Eligibility Restoration Act HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR 2761 - SPARC act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill

Client expense: $220,591 · Firm income: Not reported

Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce H.R. 3248 - Diagnostic Lab Testing Transparency Act H.R. 5378 - Lower Costs, More Transparency Act H.R. 2369 - the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 H.R. 88188 - American Privacy Rights Act of 2024 Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation CMS policies related to Medicare Advantage Engagement with executive branch departments/agencies regarding influenza A (H5) "Avian Flu"

Client expense: $520,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act

Client expense: $176,685 · Firm income: Not reported

Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce H.R. 3248 - Diagnostic Lab Testing Transparency Act H.R. 5378 - Lower Costs, More Transparency Act H.R. 2369 - the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation

Client expense: $520,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.3248, Diagnostic Lab Testing Transparency Act, Laboratory Testing related issues H.R.3561, PATIENT Act of 2023, Laboratory Testing related issues H.R.5378, The Lower Cost More Transparency Act, Laboratory Testing payment related issues FDA regulation, Laboratory Testing related issues Clinical Laboratory Improvement Amendments (CLIA), Modernization generally Monitor the following: H.R.2369, VALID Act of 2023, Diagnostic Lab Testing Pandemic All Hazards Preparedness Act, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues

Client expense: Not reported · Firm income: $30,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.3248, Diagnostic Lab Testing Transparency Act, Laboratory Testing related issues H.R.3561, PATIENT Act of 2023, Laboratory Testing related issues H.R.5378, The Lower Cost More Transparency Act, Laboratory Testing payment related issues FDA regulation, Laboratory Testing related issues Clinical Laboratory Improvement Amendments (CLIA), Modernization generally Monitor the following: H.R.2369, VALID Act of 2023, Diagnostic Lab Testing Pandemic All Hazards Preparedness Act, generally

Client expense: Not reported · Firm income: $30,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, test coding and pricing, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; price transparency for clinical laboratory services, FY 2024 budget and appropriations processes, FDA regulation of clinical laboratory services. Saving Access to Laboratory Services Act H.R. 2377/S. 1000; H.R. 3791, Improving Data in Public Health Act; H.R. 3248, Diagnostic Lab Testing Transparency Act; H.R. 5378, Lower Costs, More Transparency Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act.

Client expense: $490,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver PREVENT Pandemics Act CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA S 2140 - Patient Eligibility Restoration Act HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR 2761 - SPARC act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill

Client expense: $220,591 · Firm income: Not reported

HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver PREVENT Pandemics Act CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA S 2140 - Patient Eligibility Restoration Act HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR 2761 - SPARC act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act S.2140 - Patent Eligibility Restoration Act of 2023 Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024

Client expense: $150,705 · Firm income: Not reported

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), and Section 502 of H.R. 6363, the Further Continuing Appropriations and Other Extensions Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; H.R. 3248, the Diagnostic Lab Testing Transparency Act, Section 101 of H.R. 4822, the Health Care Price Transparency Act, Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Client expense: Not reported · Firm income: $110,000

Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce H.R. 1770 - Equitable Community Access to Pharmacist Services Act H.R. 3248 - Diagnostic Lab Testing Transparency Act H.R. 5378 - Lower Costs, More Transparency Act H.R. 2369 - the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation

Client expense: $530,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Health Care Workforce Programs and Policies. H.R. 3281, the Transparent PRICE Act. All Provisions. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. All Provisions. H.R. 3284, the Providers and Payers COMPETE Act. All Provisions. H.R. 3290, To amend title III of the Public Health Service Act. All Provisions. H.R. 3237 - Requiring a Separate Identification Number and an Attestation for Each Off-Campus Outpatient Department of a Provider. All Provisions. H.R. 3262 - Mandatory Reporting with Respect to Certain Health-Related Ownership Information. All Provisions. H.R. 3248 - The Diagnostic Lab Testing Transparency Act. All Provisions H.R. 3282 - The Promoting Transparency and Healthy Competition in Medicare Act. All Provisions H.R. 2679 - The PBM Accountability Act. All Provisions. H.R. 2559 - The Strengthening Community Care Act of 2023. All Provisions. H.R. 2550 - The Special Diabetes Program Reauthorization Act of 2023. All Provisions H.R. 2547 - The Special Diabetes Program for Indians Reauthorization Act of 2023. All Provisions. H.R. 2665 - The Supporting Safety Net Hospitals Act. All Provisions. H.R. 1613 - The Drug Price Transparency in Medicaid Act of 2023. All Provisions. S. 1002, No Unreasonable Payments, Coding, or Diagnoses for Elderly (No UPCODE Act). All Provisions. S. 1182 - 340B - To amend the Public Health Service Act to increase the transparency and accountability of the drug discount program, and for other purposes. All Provisions. S.1403 Medical Student Authorization Act of 2023. All Provisions. S.2840 Bipartisan Primary Care and Health Workforce Act. All Provisions. H.R. 5378 Lower Cost, More Transparency Act. All Provisions. Potential Grants and Procurement Programs Related to U.S. based manufacturing of Personal Protective Equipment (PPE).

Client expense: $200,000 · Firm income: Not reported

CMS'CY 2024 Advance Notice of Methodological Changes for Medicare Capitation Rates for Part C and Part D Payment Policies. Issues surrounding changes to risk adjustment mechanisms. Nomination of Chief Executive Officer for appointment to the Medicaid and CHIP Payment and Access Commission H.R. 3281, the Transparent PRICE Act. All Provisions. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. All Provisions. H.R. 3284, the Providers and Payers COMPETE Act. All Provisions. H.R. 3290, To amend title III of the Public Health Service Act. All Provisions. H.R. 3237 - Requiring a Separate Identification Number and an Attestation for Each Off-Campus Outpatient Department of a Provider. All Provisions. H.R. 3262 - Mandatory Reporting with Respect to Certain Health-Related Ownership Information. All Provisions. H.R. 3248 - The Diagnostic Lab Testing Transparency Act. All Provisions H.R. 3282 - The Promoting Transparency and Healthy Competition in Medicare Act. All Provisions H.R. 2679 - The PBM Accountability Act. All Provisions. H.R. 2559 - The Strengthening Community Care Act of 2023. All Provisions. H.R. 2550 - The Special Diabetes Program Reauthorization Act of 2023. All Provisions H.R. 2547 - The Special Diabetes Program for Indians Reauthorization Act of 2023. All Provisions. H.R. 2665 - The Supporting Safety Net Hospitals Act. All Provisions. H.R. 1613 - The Drug Price Transparency in Medicaid Act of 2023. All Provisions. S. 1002, No Unreasonable Payments, Coding, or Diagnoses for Elderly (No UPCODE Act). All Provisions. S. 1182 - 340B - To amend the Public Health Service Act to increase the transparency and accountability of the drug discount program, and for other purposes. All Provisions. H.R. 5378 Lower Cost, More Transparency Act. All Provisions. H.R. 5013 Value in Health Care Act of 2023. All Provisions. Medicaid Supplemental Payment Technical Assistance

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, test coding and pricing, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; price transparency for clinical laboratory services Reauthorization of the Pandemic and All-Hazards Preparedness Act, S.2333, Pandemic and All-Hazards Preparedness and Response Act, H.R.4420, Preparedness and Response Reauthorization Act, H.R.4421, Preparing for All Hazards and Pathogens Reauthorization Act. Reauthorization of the SUPPORT Act (P.L. 115-1271); Saving Access to Laboratory Services Act H.R. 2377/S. 1000, H.R. 3791, Improving Data in Public Health Act; H.R. 3248, Diagnostic Lab Testing Transparency Act; H.R. 4882, Clinical Laboratory Price Transparency Act of 2023 H.R. 5378, Lower Costs, More Transparency Act S. 3548, Health Care Prices and Information to Consumers Explained Transparency Act

Client expense: $544,478 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, test coding and pricing, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; price transparency for clinical laboratory services, FY 2024 budget and appropriations processes, FDA regulation of clinical laboratory services Reauthorization of the Pandemic and All-Hazards Preparedness Act, S.2333, Pandemic and All-Hazards Preparedness and Response Act, H.R.4420, Preparedness and Response Reauthorization Act, H.R.4421, Preparing for All Hazards and Pathogens Reauthorization Act. Reauthorization of the SUPPORT Act (P.L. 115-1271); Saving Access to Laboratory Services Act H.R. 2377/S. 1000, H.R. 3791, Improving Data in Public Health Act; H.R. 3248, Diagnostic Lab Testing Transparency Act; H.R. 4882, Clinical Laboratory Price Transparency Act of 2023 H.R. 5378, Lower Costs, More Transparency Act S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act

Client expense: $544,478 · Firm income: Not reported

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), and Section 502 of H.R. 6363, the Further Continuing Appropriations and Other Extensions Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; H.R. 3248, the Diagnostic Lab Testing Transparency Act, Section 101 of H.R. 4822, the Health Care Price Transparency Act, Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; The Fiscal Year 2024 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the U.S. Preventive Services Task Force; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Client expense: $250,000 · Firm income: Not reported

HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver PREVENT Pandemics Act CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA S 2140 - Patient Eligibility Restoration Act HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR 2761 - SPARC act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act S.2140 - Patent Eligibility Restoration Act of 2023

Client expense: $141,488 · Firm income: Not reported

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; S. 2333, the Pandemic and All-Hazards Prevention and Response Act, Section 204, provisions relating to a pilot program for public health data availability; H.R. 3791, the Improving DATA in Public Health Act, Section 107 of H.R. 4420, the Preparedness and Response Authorization Act, and H.R. 3742, a bill to direct a GAO study to evaluate the Federal Governments collection and sharing of public health data to respond to public health emergencies, provisions relating to demographic data reporting obligations for laboratories; S. 2483, the Strengthening Consumer Protections and Medical Debt Transparency Act, provisions relating to medical debt; H.R. 3248, the Diagnostic Lab Testing Transparency Act, Section 101 of H.R. 4822, the Health Care Price Transparency Act, Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, provisions relating to publication of rates for laboratory services; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; The Fiscal Year 2024 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the U.S. Preventive Services Task Force; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Implementation of Protecting Access to Medicare Act of 2014, P.L.113-93 (changes to reimbursement for clinical laboratory services). Policies impacting Medicare coverage and reimbursement for clinical laboratory services. FDA regulation of clinical laboratory services. Coronavirus impact and response. H.R.2377/S.1000, Saving Access to Laboratory Services Act. H.R.3791, Improving DATA in Public Health Act. H.R.3248, Diagnostic Lab Testing Transparency Act. FY 2024 budget and appropriations process. Reauthorization of the Pandemic and All-Hazards Preparedness Act, S.2333, Pandemic and All-Hazards Preparedness and Response Act, H.R.4420, Preparedness and Response Reauthorization Act, H.R.4421, Preparing for All Hazards and Pathogens Reauthorization Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Monitor implementation of H.R. 6201, the Families First Coronavirus Response Act (Public Law 116-127), and provisions related to clinical laboratory testing for COVID-19, including coverage and reimbursement of COVID-19 tests Monitor implementation of H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act, the CARES Act, (Public Law 116-136), and provisions related to clinical laboratory testing for COVID-19, including coverage and reimbursement of COVID-19 tests, laboratory data collection and reimbursement under PAMA, and laboratory data reporting H.R.1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2) and provisions related to clinical laboratory testing for COVID-19 H.R. 2369 - the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 Federal policy and programs ensuring an equitable pandemic response and recovery, including coverage of COVID-19 testing services for uninsured patients Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship H.R. 4363 - The Comprehensive Cancer Survivorship Act Federal policy related to strengthening the clinical laboratory workforce Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) H.R. 1770 - Equitable Community Access to Pharmacist Services Act H.R. 3248 - Diagnostic Lab Testing Transparency Act

Client expense: $530,000 · Firm income: Not reported

Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act H.R. 4420 - Preparedness and Response Reauthorization Act H.R. 1770 - Equitable Community Access to Pharmacist Services Act H.R. 3248 - Diagnostic Lab Testing Transparency Act H.R. 5378 - Lower Costs, More Transparency Act H.R. 2369 - the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 Federal policy related to the regulation of Laboratory Developed Tests (LDT)

Client expense: $520,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; H.R. 3791, the Improving DATA in Public Health Act, Section 107 of H.R. 4420, the Preparedness and Response Authorization Act, and H.R. 3742, a bill to direct a GAO study to evaluate the Federal Governments collection and sharing of public health data to respond to public health emergencies, provisions relating to demographic data reporting obligations for laboratories; H.R. 3248, the Diagnostic Lab Testing Transparency Act, Section 101 of H.R. 4822, the Health Care Price Transparency Act, Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, provisions relating to publication of rates for laboratory services; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Client expense: Not reported · Firm income: $110,000

CMS'CY 2024 Advance Notice of Methodological Changes for Medicare Capitation Rates for Part C and Part D Payment Policies. Issues surrounding changes to risk adjustment mechanisms. Nomination of Chief Executive Officer for appointment to the Medicaid and CHIP Payment and Access Commission H.R. 3281, the Transparent PRICE Act. All Provisions. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. All Provisions. H.R. 3284, the Providers and Payers COMPETE Act. All Provisions. H.R. 3290, To amend title III of the Public Health Service Act. All Provisions. H.R. 3237 - Requiring a Separate Identification Number and an Attestation for Each Off-Campus Outpatient Department of a Provider. All Provisions. H.R. 3262 - Mandatory Reporting with Respect to Certain Health-Related Ownership Information. All Provisions. H.R. 3248 - The Diagnostic Lab Testing Transparency Act. All Provisions H.R. 3282 - The Promoting Transparency and Healthy Competition in Medicare Act. All Provisions H.R. 2679 - The PBM Accountability Act. All Provisions. H.R. 2559 - The Strengthening Community Care Act of 2023. All Provisions. H.R. 2550 - The Special Diabetes Program Reauthorization Act of 2023. All Provisions H.R. 2547 - The Special Diabetes Program for Indians Reauthorization Act of 2023. All Provisions. H.R. 2665 - The Supporting Safety Net Hospitals Act. All Provisions. H.R. 1613 - The Drug Price Transparency in Medicaid Act of 2023. All Provisions. S. 1002, No Unreasonable Payments, Coding, or Diagnoses for Elderly (No UPCODE Act). All Provisions. S. 1182 - 340B - To amend the Public Health Service Act to increase the transparency and accountability of the drug discount program, and for other purposes. All Provisions. H.R. 5378 Lower Cost, More Transparency Act. All Provisions. H.R. 5013 Value in Health Care Act of 2023. All Provisions.

Health Care Workforce Programs and Policies. H.R. 3281, the Transparent PRICE Act. All Provisions. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. All Provisions. H.R. 3284, the Providers and Payers COMPETE Act. All Provisions. H.R. 3290, To amend title III of the Public Health Service Act. All Provisions. H.R. 3237 - Requiring a Separate Identification Number and an Attestation for Each Off-Campus Outpatient Department of a Provider. All Provisions. H.R. 3262 - Mandatory Reporting with Respect to Certain Health-Related Ownership Information. All Provisions. H.R. 3248 - The Diagnostic Lab Testing Transparency Act. All Provisions H.R. 3282 - The Promoting Transparency and Healthy Competition in Medicare Act. All Provisions H.R. 2679 - The PBM Accountability Act. All Provisions. H.R. 2559 - The Strengthening Community Care Act of 2023. All Provisions. H.R. 2550 - The Special Diabetes Program Reauthorization Act of 2023. All Provisions H.R. 2547 - The Special Diabetes Program for Indians Reauthorization Act of 2023. All Provisions. H.R. 2665 - The Supporting Safety Net Hospitals Act. All Provisions. H.R. 1613 - The Drug Price Transparency in Medicaid Act of 2023. All Provisions. S. 1002, No Unreasonable Payments, Coding, or Diagnoses for Elderly (No UPCODE Act). All Provisions. S. 1182 - 340B - To amend the Public Health Service Act to increase the transparency and accountability of the drug discount program, and for other purposes. All Provisions. S.1403 Medical Student Authorization Act of 2023. All Provisions. S.2840 Bipartisan Primary Care and Health Workforce Act. All Provisions. H.R. 5378 Lower Cost, More Transparency Act. All Provisions.

Client expense: $175,000 · Firm income: Not reported

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; price transparency for clinical laboratory services, FY 2024 budget and appropriations processes, FDA regulation of clinical laboratory services, Reauthorization of the Pandemic and All-Hazards Preparedness Act, S.2333, Pandemic and All-Hazards Preparedness and Response Act, H.R.4420, Preparedness and Response Reauthorization Act, H.R.4421, Preparing for All Hazards and Pathogens Reauthorization Act. Reauthorization of the SUPPORT Act (P.L. 115-1271); Saving Access to Laboratory Services Act H.R. 2377/S. 1000, H.R. 3791, Improving Data in Public Health Act; H.R. 3248, Diagnostic Lab Testing Transparency Act; H.R. 4882, Clinical Laboratory Price Transparency Act of 2023 H.R. 5378, Lower Costs, More Transparency Act

Client expense: $739,813 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; price transparency for clinical laboratory services, FY 2024 budget and appropriations processes, FDA regulation of clinical laboratory services, Reauthorization of the Pandemic and All-Hazards Preparedness Act, S.2333, Pandemic and All-Hazards Preparedness and Response Act, H.R.4420, Preparedness and Response Reauthorization Act, H.R.4421, Preparing for All Hazards and Pathogens Reauthorization Act. Reauthorization of the SUPPORT Act (P.L. 115-1271); Saving Access to Laboratory Services Act H.R. 2377/S. 1000, H.R. 3791, Improving Data in Public Health Act; H.R. 3248, Diagnostic Lab Testing Transparency Act; H.R. 4882, Clinical Laboratory Price Transparency Act of 2023 H.R. 5378, Lower Costs, More Transparency Act

Client expense: $739,813 · Firm income: Not reported

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; S. 2333, the Pandemic and All-Hazards Prevention and Response Act, Section 204, provisions relating to a pilot program for public health data availability; H.R. 3791, the Improving DATA in Public Health Act, Section 107 of H.R. 4420, the Preparedness and Response Authorization Act, and H.R. 3742, a bill to direct a GAO study to evaluate the Federal Governments collection and sharing of public health data to respond to public health emergencies, provisions relating to demographic data reporting obligations for laboratories; S. 2483, the Strengthening Consumer Protections and Medical Debt Transparency Act, provisions relating to medical debt; H.R. 3248, the Diagnostic Lab Testing Transparency Act, Section 101 of H.R. 4822, the Health Care Price Transparency Act, Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, provisions relating to publication of rates for laboratory services; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; The Fiscal Year 2024 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the U.S. Preventive Services Task Force; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665 - Conrad 30 and Physician Access Reauthorization Act CLIA Waiver PREVENT Pandemics Act CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology SALSA S 2140 - Patient Eligibility Restoration Act HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR 2761 - SPARC act HR 2764/S1229 - Green New Deal for Health HR 2474 - Medicare inflationary update HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023

Client expense: $98,569 · Firm income: Not reported

Implementation of Protecting Access to Medicare Act of 2014, P.L.113-93 (changes to reimbursement for clinical laboratory services). Policies impacting Medicare coverage and reimbursement for clinical laboratory services. FDA regulation of clinical laboratory services. Coronavirus impact and response. H.R.2377/S.1000, Saving Access to Laboratory Services Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act. H.R.3791, Improving DATA in Public Health Act. H.R.3248, Diagnostic Lab Testing Transparency Act. FY 2024 budget and appropriations process.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 751, Fair Access In Residency (FAIR) Act, all provisions H.R. 1610, Chiropractic Medicare Coverage Modernization Act of 2023, all provisions S. 799, Chiropractic Medicare Coverage Modernization Act of 2023, all provisions H.R. 2474, Strengthening Medicare for Patients and Providers Act, all provisions H.R. 2829, Chronic Care Management Improvement Act of 2023, all provisions H.R. 1770, Equitable Community Access to Pharmacist Services Act, all provisions H.R. 2377, Saving Access to Laboratory Services (SALSA) Act, all provisions S. 1000, Saving Access to Laboratory Services (SALSA) Act, all provisions S. 703, Physicians for Underserved Areas Act, all provisions H.R. 977, Patient Access to Higher Quality Health Care Act of 2023, all provisions S. 470, Patient Access to Higher Quality Health Care Act of 2023, all provisions H.R. 1694, Emergency Care Improvement Act, all provisions H.R. 4189, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023, all provisions S. 2016, A bill to amend title XVIII of the Social Security Act to expand access to telehealth services, and for other purposes, all provisions H.R. 1745, Medicare Fraud Detection and Deterrence Act of 2023, all provisions H.R. 1746, Preventing Medicare Telefraud Act, all provisions S. 1491, Pharmacy and Medically Underserved Areas Enhancement Act, all provisions S. 1246, Strengthening Medicare And Reducing Taxpayer (SMART) Prices Act, all provisions H.R. 2811, Limit, Save, Grow Act of 2023, provisions relating to Medicaid work requirements H.R. 3746, Fiscal Responsibility Act of 2023, provisions relating to Medicaid work requirements H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023, provisions relating to Sections 101 and 105 H.R. 3281, Transparent PRICE Act, all provisions H.R. 3248, Diagnostic Lab Testing Transparency Act, all provisions S. 669, Increasing Mental Health Options Act of 2023, all provisions H.R. 2713, Improving Care and Access to Nurses (I CAN) Act, all provisions H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information, all provisions H.R. 496, Freedom for Health Care Workers Act, all provisions S. 1606, Black Maternal Health Momnibus Act, all provisions S. 712, Connected MOM Act, all provisions S. 1339, Pharmacy Benefit Manager Reform Act, all provisions H.R. 2389, Resident Physician Shortage Reduction Act of 2023, all provisions S. 1302, Resident Physician Shortage Reduction Act of 2023, all provisions Amputation Reduction and Compassion (ARC) Act, all provisions Promoting Responsible and Effective Virtual Experiences through Novel Technology to Deliver Improved Access and Better Engagement with Tested and Evidence-based Strategies (PREVENT DIABETES) Act, all provisions Opioid Workforce Act, all provisions Substance Use Disorder Workforce Act, all provisions Increasing Mental Health Options Act/House draft/psychologists prescribing Value in Healthcare Act CONNECT for Health Act Chronic Care Management Improvement Act of 2023 Medicare program: Making Care Primary/alternative payment model Medicare program: Surprise medical billing Medicare program: Physician payment reform Medicare program: Physician inflation updates/Medicare Economic Index (MEI) Medicare program: Budget neutrality Medicare program: Physician-owned hospitals Medicare program: Merit-based Incentive Payment System (MIPS) reforms/quality/cost/promoting interoperability/data sharing Medicare program: MIPS/MSSP/Data Completeness and eCQM Adoption Medicare program: Quality Payment Program/physician burdens Medicare program: Medicare Payment Advisory Commission (MedPAC)/physician payment reform recommendations Medicare program: Medicare Physician Payment - Add-on code Medicare program: Medicare Advantage/Prior Authorization Medicare program: Prior authorization regulation/include major provisions of Improving Seniors Timely Access to Care Act Medicare program: Site Neutral Payment Policies Medicare program: Medicare telehealth restrictions/permanent repeal Medicare program: Health IT/physician burdens Medicare program: Medicare Advantage cuts/Advanced Rate Notice Medicare program: Electronic Health Records (EHR) certification Medicare program: Remote patient monitoring/local coverage determinations Medicare program: Patient engagement/quality data reporting Medicare program: Residents in teaching settings/supervision through real-time audio visual technology Medicare program: Provider Enrollment, Chain, and Ownership System (PECOS)/enrollment and validation Medicare program: Open Payments Medicare program: Prior authorization study update Medicare and Medicaid programs: 21st Century Cures Act/implementation Medicare and Medicaid programs: Medicare Access and CHIP Reauthorization (MACRA) Act/Broad reform Medicare and Medicaid programs: MACRA/physician burdens Medicare and Medicaid programs: Cybersecurity/Information Blocking Medicare and Medicaid programs: Coding Medicare and Medicaid programs: Substance use disorder Medicare and Medicaid programs: Data privacy Medicare and Medicaid programs: HIPAA/electronic health records Medicare and Medicaid programs: Puerto Rico/physician payment inequities/access to care Medicare and Medicaid programs: Undocumented immigrants/access to care Medicaid program: Unwinding continuous enrollment

Monitor implementation of H.R. 6201, the Families First Coronavirus Response Act (Public Law 116-127), and provisions related to clinical laboratory testing for COVID-19, including coverage and reimbursement of COVID-19 tests Monitor implementation of H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act, the CARES Act, (Public Law 116-136), and provisions related to clinical laboratory testing for COVID-19, including coverage and reimbursement of COVID-19 tests, laboratory data collection and reimbursement under PAMA, and laboratory data reporting H.R.1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2) and provisions related to clinical laboratory testing for COVID-19 H.R. 2369 - the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 Federal policy and programs ensuring an equitable pandemic response and recovery, including coverage of COVID-19 testing services for uninsured patients Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship H.R. 4363 - The Comprehensive Cancer Survivorship Act Federal policy related to strengthening the clinical laboratory workforce Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) H.R. 1770 - Equitable Community Access to Pharmacist Services Act H.R. 3248 - Diagnostic Lab Testing Transparency Act

Client expense: $580,000 · Firm income: Not reported

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; H.R. 3791, the Improving DATA in Public Health Act, and H.R. 3742, a bill to direct a GAO study to evaluate the Federal Governments collection and sharing of public health data to respond to public health emergencies, provisions relating to demographic data reporting obligations for laboratories; H.R. 3248, the Diagnostic Lab Testing Transparency Act, and Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, provisions relating to publication of rates for laboratory services; Federal policy related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI); Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Client expense: Not reported · Firm income: $110,000

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); price transparency for clinical laboratory services, FY 2024 budget and appropriations processes Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369; H.R. 3791, Improving Data in Public Health Act; H.R. 3248, Diagnostic Lab Testing Transparency Act;

Client expense: $633,739 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); price transparency for clinical laboratory services, FY 2024 budget and appropriations processes Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369; H.R. 3791, Improving Data in Public Health Act; H.R. 3248, Diagnostic Lab Testing Transparency Act;

Client expense: $633,739 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; H.R. 3791, the Improving DATA in Public Health Act, and H.R. 3742, a bill to direct a GAO study to evaluate the Federal Governments collection and sharing of public health data to respond to public health emergencies, provisions relating to demographic data reporting obligations for laboratories; H.R. 3795, the Diagnostic Testing Preparedness Plan Act, and H.R. 3840, the Ensuring Sufficient Supply of Testing Act, provisions relating to laboratory testing capabilities in connection with reauthorization of the Pandemics and All-Hazards Preparedness Act; H.R. 3248, the Diagnostic Lab Testing Transparency Act, and Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, provisions relating to publication of rates for laboratory services; The Patent Eligibility Restoration Act of 2023, provisions relating to patent subject matter eligibility; The American Data Privacy and Protection Act (ADPPA), provisions relating to data privacy; Federal policy related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI); Federal policy related to oversight of artificial intelligence; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

CMS'CY 2024 Advance Notice of Methodological Changes for Medicare Capitation Rates for Part C and Part D Payment Policies. Issues surrounding changes to risk adjustment mechanisms. Nomination of Chief Executive Officer for appointment to the Medicaid and CHIP Payment and Access Commission H.R. 3281, the Transparent PRICE Act. All Provisions. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. All Provisions. H.R. 3284, the Providers and Payers COMPETE Act. All Provisions. H.R. 3290, To amend title III of the Public Health Service Act. All Provisions. H.R. 3237 - Requiring a Separate Identification Number and an Attestation for Each Off-Campus Outpatient Department of a Provider. All Provisions. H.R. 3262 - Mandatory Reporting with Respect to Certain Health-Related Ownership Information. All Provisions. H.R. 3248 - The Diagnostic Lab Testing Transparency Act. All Provisions H.R. 3282 - The Promoting Transparency and Healthy Competition in Medicare Act. All Provisions H.R. 2679 - The PBM Accountability Act. All Provisions. H.R. 2559 - The Strengthening Community Care Act of 2023. All Provisions. H.R. 2550 - The Special Diabetes Program Reauthorization Act of 2023. All Provisions H.R. 2547 - The Special Diabetes Program for Indians Reauthorization Act of 2023. All Provisions. H.R. 2665 - The Supporting Safety Net Hospitals Act. All Provisions. H.R. 1613 - The Drug Price Transparency in Medicaid Act of 2023. All Provisions. S. 1002, No Unreasonable Payments, Coding, or Diagnoses for Elderly (No UPCODE Act). All Provisions. S. 1182 - 340B - To amend the Public Health Service Act to increase the transparency and accountability of the drug discount program, and for other purposes. All Provisions.

Client expense: $175,000 · Firm income: Not reported

Health Care Workforce Programs and Policies. H.R. 3281, the Transparent PRICE Act. All Provisions. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. All Provisions. H.R. 3284, the Providers and Payers COMPETE Act. All Provisions. H.R. 3290, To amend title III of the Public Health Service Act. All Provisions. H.R. 3237 - Requiring a Separate Identification Number and an Attestation for Each Off-Campus Outpatient Department of a Provider. All Provisions. H.R. 3262 - Mandatory Reporting with Respect to Certain Health-Related Ownership Information. All Provisions. H.R. 3248 - The Diagnostic Lab Testing Transparency Act. All Provisions H.R. 3282 - The Promoting Transparency and Healthy Competition in Medicare Act. All Provisions H.R. 2679 - The PBM Accountability Act. All Provisions. H.R. 2559 - The Strengthening Community Care Act of 2023. All Provisions. H.R. 2550 - The Special Diabetes Program Reauthorization Act of 2023. All Provisions H.R. 2547 - The Special Diabetes Program for Indians Reauthorization Act of 2023. All Provisions. H.R. 2665 - The Supporting Safety Net Hospitals Act. All Provisions. H.R. 1613 - The Drug Price Transparency in Medicaid Act of 2023. All Provisions. S. 1002, No Unreasonable Payments, Coding, or Diagnoses for Elderly (No UPCODE Act). All Provisions. S. 1182 - 340B - To amend the Public Health Service Act to increase the transparency and accountability of the drug discount program, and for other purposes. All Provisions.

Client expense: $175,000 · Firm income: Not reported